ACUTECT
LOE ApproachingPeptidetechnetium tc-99m apcitide
NDAINJECTIONINJECTABLEPriority Review
Approved
Sep 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACUTECT is a radiopharmaceutical diagnostic agent containing Technetium Tc-99m apcitide, used for acute infection and inflammation imaging via injection. It functions as a molecular imaging tracer that localizes to sites of bacterial infection and inflammatory lesions. The drug enables healthcare providers to visualize and diagnose acute infections non-invasively using nuclear medicine imaging.
LOE Approaching
As a legacy radiopharmaceutical approaching loss of exclusivity with minimal current commercial activity, career opportunities are limited and focused on transition or maintenance of existing infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ACUTECT offers limited career advancement potential given its mature lifecycle stage and approaching loss of exclusivity. Roles focus primarily on maintaining existing business and managing transition strategy rather than growth or innovation.
Product ManagerRegional Sales Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.